抗癌生物制剂对眼睛表面的不良影响
Riham Shawer1,2, Abraham Solomon1
1Department of Ophthalmology, Hadassah-Hebrew University Medical Centre.
Current opinion in allergy and clinical immunology
|July 4, 2024
概括
癌症免疫疗法,像免疫检查点抑制剂一样,经常导致眼部副作用. 及时诊断和管理对于预防视力丧失和维持患者的生活质量至关重要.
科学领域:
- 眼科医生 眼科 眼科
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 癌症免疫疗法,特别是免疫检查点抑制剂 (ICI) 和表皮生长因子受体 (EGFR) 抑制剂,是一个快速发展的领域.
- 眼部副作用很普遍,影响到接受这些治疗的患者中高达70%的患者.
- 角膜的干扰可以从轻微的刺激到严重的和视力丧失.
研究的目的:
- 审查接受免疫治疗的癌症患者眼表面副作用的发生率.
- 为了阐明这些免疫疗法诱导的眼部并发症背后的机制.
- 概述眼表面和角膜不良事件的管理策略.
主要方法:
- 对癌症免疫疗法和眼部副作用研究的文献综述.
- 分析各种免疫治疗剂触发的致病机制.
- 对眼科医生和瘤学家的当前管理指南的综合.
主要成果:
- 免疫检查点抑制剂 (ICI) 和EGFR抑制剂经常与眼表面和角膜并发症有关.
- 这些情况带来了视力威胁的并发症的风险,需要谨慎监测.
- 角质干预通过各种致病途径表现出来.
结论:
- 与免疫疗法相关的角膜并发症显著降低了患者的生活质量.
- 早期识别和诊断眼部不良事件至关重要.
- 涉及眼科医生和瘤学家的跨学科方法对于有效的管理和保持眼睛完整性至关重要.
相关概念视频
Open Angle Glaucoma: Treatment
427
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
427
Glaucoma: Overview
538
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
538
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Angle Closure Glaucoma: Treatment
470
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
470
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
128
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
128


